Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation

Labcorp’s One-Month Rally Sets a Higher Bar

Labcorp’s 14% four-week gain stands out against an already stronger operating backdrop. The company’s Diagnostics Laboratories business grew revenues 5.5% year over year in the second quarter, while Biopharma Laboratory Services, or BLS, advanced 6.5%.

The move does not establish that any single development drove the stock higher. It does, however, raise expectations as investors assess whether improving profitability, specialty testing demand and biopharma activity can sustain the recent momentum.

LH’s Q2 Results Add Fundamental Support

Second-quarter adjusted earnings were $4.99 per share, up 14.9% year over year and 4.2% above the Zacks Consensus Estimate. Revenues increased 5.8% to $3.73 billion and also topped the consensus mark.

Profitability improved with the top line. Adjusted operating income rose to $588.7 million from $531.6 million, while the enterprise adjusted operating margin expanded 70 basis points to 15.8%. The margin gain shows that revenue growth is translating into better operating leverage.

In the past 30 days, Labcorp’s 2026 earnings have moved north by 1.3% to $18.24. 

Image Source: Zacks Investment Research

Labcorp’s Growth Drivers Still Have Room to Run

Specialty testing remains a central growth engine. Oncology, women’s health, autoimmune disease and neurology each delivered double-digit revenue growth during the first half of 2026, supporting new health-system and provider wins and a favorable test mix.

BLS adds another source of momentum. Second-quarter revenue rose 6.5% to $836.2 million, Central Laboratories revenue increased 9.8% and the segment’s adjusted operating margin reached 17%. Quest Diagnostics Incorporated DGX, another large diagnostic testing provider, offers investors a direct industry comparison for laboratory demand and health-system relationships. Thermo Fisher Scientific Inc. TMO also provides a relevant biopharma-services reference point through its broad pharmaceutical and clinical research capabilities.

LH’s Valuation Raises the Priced-In Question

Labcorp trades at 16.7X forward 12-month earnings, modestly above the Zacks sub-industry’s 16.2X multiple. It also sits well above its own five-year median of 14.4X, although the current multiple remains below the five-year high of 17.8X.

Image Source: Zacks Investment Research

That premium does not negate the company’s improving results, but it reduces the room for disappointment. Further upside will likely require continued earnings execution, sustained specialty and BLS growth and additional margin progress to justify a valuation already above Labcorp’s longer-term norm.

Labcorp’s Ratings Favor Momentum Over Growth

The near-term setup is balanced rather than one-sided. Labcorp currently carries a Zacks Rank #3 (Hold), which points to a neutral short-term earnings-revision backdrop rather than a clear buy or sell signal.

The Style Scores tilt more favorably toward momentum and value. Labcorp has a VGM Score of B, Momentum Score of A and Value Score of B, while its Growth Score is C. The mix fits the current tension: price momentum and valuation characteristics are favorable, but the pure-growth profile is less compelling. After the recent rally, execution remains important as investors weigh business progress against a richer valuation.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research